Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.

Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: A Consensus-Driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014. e1.

Article  CAS  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56.

Article  CAS  PubMed  Google Scholar 

Polyzos SA, Mantzoros CS. Metabolic dysfunction-associated steatotic liver disease: recent turning points for its diagnosis and management. Metabolism. 2024;155936.

Pais R, Maurel T. Natural history of NAFLD. J Clin Med. 2021;10:1161.

Article  PubMed  PubMed Central  Google Scholar 

Wong VW-S, Ekstedt M, Wong GL-H, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842–52.

Article  PubMed  Google Scholar 

Schwärzler J, Grabherr F, Grander C, Adolph TE, Tilg H. The pathophysiology of MASLD: an immunometabolic perspective. Expert Rev Clin Immunol. 2024;20:375–86.

Article  PubMed  Google Scholar 

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389 – 97.e10.

Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:92–108.

Article  PubMed  Google Scholar 

Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691–702.

CAS  PubMed  Google Scholar 

Vachliotis ID, Vasiloglou MF, Kapama A, Matsagkos D, Goulas A, Papaioannidou P, et al. Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life. Arab J Gastroenterol. 2022;23:277–87.

Article  PubMed  Google Scholar 

Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223–38.

Article  PubMed  Google Scholar 

Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99–128.

Article  CAS  PubMed  Google Scholar 

Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349–64.

Article  CAS  PubMed  Google Scholar 

Mladenić K, Lenartić M, Marinović S, Polić B, Wensveen FM. The domino effect in MASLD: the inflammatory cascade of steatohepatitis. Eur J Immunol. 2024;54:e2149641.

Article  PubMed  Google Scholar 

Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol. 2022;77:1136–60.

Article  CAS  PubMed  Google Scholar 

Cebi M, Yilmaz Y. Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes. Front Immunol. 2024;15:1445634.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers. 2021;13:730.

Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J. Hepatol. Elsevier BV; 2024. pp. e76–7.

Vachliotis ID, Valsamidis I, Polyzos SA. Tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Cancers (Basel). 2023;15:5306.

Article  CAS  PubMed  Google Scholar 

Vachliotis ID, Polyzos SA. The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease. Curr Obes Rep. 2023;12:191–206.

Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem. 2011;22:527–34.

Article  CAS  PubMed  Google Scholar 

Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res. 2018;50:80–7.

Article  CAS  PubMed  Google Scholar 

Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–50.

Article  CAS  PubMed  Google Scholar 

Wandrer F, Liebig S, Marhenke S, Vogel A, John K, Manns MP, et al. TNF-Receptor-1 Inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis. 2020;11:212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol. 2021;36:3002–14.

Article  CAS  PubMed  Google Scholar 

Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, et al. Association of inflammatory cytokines with Non-Alcoholic fatty liver disease. Front Immunol. 2022;13:880298.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seo YY, Cho YK, Bae J-C, Seo MH, Park SE, Rhee E-J, et al. Tumor necrosis Factor-α as a predictor for the development of nonalcoholic fatty liver disease: A 4-Year Follow-Up study. Endocrinol Metab (Seoul). 2013;28:41–5.

Article  PubMed  Google Scholar 

Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, Williams J, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol. 2009;24:443–52.

Article  CAS  PubMed  Google Scholar 

Affò S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O, et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut. 2013;62:452–60.

Article  PubMed  Google Scholar 

Idrissova L, Malhi H, Werneburg NW, LeBrasseur NK, Bronk SF, Fingas C, et al. TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. J Hepatol. 2015;62:1156–63.

Article  CAS  PubMed  Google Scholar 

Hirsova P, Weng P, Salim W, Bronk SF, Griffith TS, Ibrahim SH, et al. TRAIL deletion prevents liver, but not adipose tissue, inflammation during murine Diet-Induced obesity. Hepatol Commun. 2017;1:648–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007;56:1124–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286:39336–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernardi S, Toffoli B, Tisato V, Bossi F, Biffi S, Lorenzon A, et al. TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. Clin Sci. 2018;132:69–83.

Article  CAS  Google Scholar 

Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, et al. Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice. Sci Rep. 2017;7:1898.

Article  PubMed  PubMed Central